Disitamab Vedotin not checked
RemeGen · RC48-ADC · RC48
FollowEvery change as it happens, and a Monday email
Trials
16 active
29 in total
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Disitamab Vedotin: 2.5 mg/kg, IV, D1, Q2W; Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 100 mg/m², IV, D1, Q3W; Capecitabine: 750 mg/m², po, BID, D1-D14, Q3W”In the company’s words, NCT06944496 on ClinicalTrials.gov
- Tested for
- Breast Cancer (5 trials), Gastric Cancer (3 trials), Gastric Carcinoma (2 trials), Gastroesophageal Junction Adenocarcinoma (2 trials), Urothelial Carcinoma, HER2-expressing, NMIBC, Cervical Cancer and 3 more
- Main trialPhase 3
- “This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.”In the company’s words, NCT05302284 on ClinicalTrials.gov
- Other names
- RC48-ADC · DV · RC48
Other drugs for Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up8
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- DecPhase 2/3 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 15 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 15 Mar 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Jun 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials29
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2026 | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | |
| Phase 3Recruiting | 31 Dec 2027 | A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | |
| Phase 3Not yet recruiting | 15 May 2028 | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | |
| Phase 3Recruiting | 30 Jun 2029 | A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. | |
| Phase 2/3Active, not recruiting | 10 Jul 2025 | A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | |
| Phase 2/3Recruiting | Dec 2026 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | |
| Phase 2Recruiting | 31 Jan 2025 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | |
| Phase 2Recruiting | 1 Jun 2025 | To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer | |
| Phase 2Recruiting | 1 Dec 2025 | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | |
| Phase 2Recruiting | Dec 2025 | Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | |
| Phase 2Recruiting | Jun 2026 | DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer | |
| Phase 2Recruiting | 1 Oct 2026 | Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer | |
| Phase 2Recruiting | 30 Jun 2027 | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer | |
| Phase 1/2Not yet recruiting | 1 Dec 2027 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | |
| Phase 1/2Recruiting | 15 Mar 2029 | To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 | |
| Phase 1Recruiting | 16 Nov 2024 | RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression | |
| Phase 3Unknown | 1 Dec 2024 | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | |
| Phase 2/3Unknown | 31 Jul 2024 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | |
| Phase 2Completed | 1 Jun 2020 | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2 | |
| Phase 2Completed | 4 Mar 2021 | A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer | |
| Phase 2Completed | 30 Sep 2022 | A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer | |
| Phase 2Unknown | 3 Nov 2023 | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer | |
| Phase 2Unknown | 1 Jun 2024 | A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | |
| Phase 2Unknown | Oct 2024 | A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies | |
| Phase 2Unknown | 30 Dec 2024 | A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) | |
| Phase 2Withdrawn | 20 Dec 2025 | Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer | |
| Phase 2Unknown | Dec 2025 | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer | |
| Phase 1/2Completed | 31 Jul 2022 | A Study of RC48-ADC in Subjects With Advanced Breast Cancer | |
| Phase 1Unknown | 30 May 2024 | To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026